The effect of antithrombotic therapy on the recurrence of placenta-mediated diseases in pregnancy

References

• Kim MJ, Kim SY, Park SY, et al. Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications. Placenta. 2013;34(1):57–61.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Betancourt MT, Clark P, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications. A systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010;7(6):e1000292.
   PubMed Web of Science ®Google Scholar
• Chevreau J, Tonini F, Attencourt C, et al. Can certain factors for recurrence of placenta-mediated pregnancy complications be identified after an initial small-for-gestational-age birth? The J Mat-Fet Neonat Med. 2020;33(11):1895–1900.
   PubMed Web of Science ®Google Scholar
• Greer IA, Aharon A, Brenner B, et al. Coagulation and placenta-mediated complications. Rambam Maimonides Med J. 2014;5(4):e0034.
   PubMedGoogle Scholar
• Skeith L, Rodger M. Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: is it time to put the needles away? Thrombosis Res. 2017;151(1):S38–S42.
   PubMedGoogle Scholar
• Gomathy E, Lahari A, Kondareddy R. Early-onset and late onset preeclampsia – maternal and perinatal outcomes in a rural tertiary health center. Int J Reprod, Contracept, Obstet Gynecol. 2018;7(6):2266–2269.
   Google Scholar
• Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497–506.
   PubMed Web of Science ®Google Scholar
• Boyd HA, Tahir H, Wohlfahrt J, et al. Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclapmsia. Am J Epidemiol. 2013;178(11):1611–1619.
   PubMed Web of Science ®Google Scholar
• Vayssière C, Sentilhes L, Ego A, et al. Fetal growth restriction and intrauterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. Euro J Obstet, Gynecol Reprod Biol. 2015;193:10–18.
   PubMed Web of Science ®Google Scholar
• Tikkanen M. Placental abruption: epidemiology, risk factors and consequences. Acta Obstetricia et Gynecologica Scandinavica. 2011;90(2):140–149.
   PubMed Web of Science ®Google Scholar
• Flenady V, Frøen JF, Pinar H, et al. An evaluation of classification systems for stillbirth. BMC Pregnancy Childbirth. 2009;9(1):24.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Carrier M, Le Gal G, et al. Metaanalysis of low molecular weight heparin to prevent recurrent placenta mediated pregnancy complications. Blood. 2014;123(6):822–828.
   PubMed Web of Science ®Google Scholar
• Thériault T, Touchette M, Goupil V, et al. Thromboprophylaxis adherence to the ninth edition of American college of chest physicians antithrombotic guidelines in a tertiary care centre: a cross sectional study. J Eval Clin Pract. 2016;22(6):956–961.
   Web of Science ®Google Scholar
• Panagodage S, Yong HE, Da Silva Costa F, et al. Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia. Am J Pathol. 2016;186(12):3217–3224.
   PubMed Web of Science ®Google Scholar
• Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia (NOH-PE trial). Thromb Haemost. 2011;106(12):1053–1061.
   PubMedGoogle Scholar
• Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose Aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141–146.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388(10060):2629–2641.
   PubMed Web of Science ®Google Scholar
• Rodger MA. Anticoagulant prophylaxis for placenta mediated pregnancy complications. Thrombosis Res. 2011;127(3):S76–S80.
   PubMedGoogle Scholar
• Patrick J, Dillaha L, Armas D, et al. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgraduate Med. 2015;127(6):573–580.
   PubMed Web of Science ®Google Scholar
• Li C, Raikwar NS, Santillan MK, et al. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36(4):446–453.
   PubMed Web of Science ®Google Scholar
• O’Gorman N, Wright D, Rolnik DL, et al. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with aspirin for evidence-based preeclampsia prevention (ASPRE). Brit Med J. 2016;6(6):e011801.
   PubMed Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2):402–414.
   PubMed Web of Science ®Google Scholar
• Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae (the pilot randomized controlled NOH-AP trial). Thromb Haemost. 2010;104(10):771–779.
   PubMedGoogle Scholar
• Sotiriadis A. Low-dose aspirin plus low-molecular-weight heparin for the prevention of pre-eclampsia: yes, no or maybe. Ultrasound Obstet Gynecol. 2016;47(5):539–541.
   PubMed Web of Science ®Google Scholar
• De Vries JI, van Pampus MG, Hague WM, et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemostasis. 2012;10(1):64–72.
   PubMed Web of Science ®Google Scholar